In recent years, benefits of Highly Active Antiretroviral Therapy (HAART) conferred on the morbidity and mortality of HIV/AIDS patients have been observed in numerous studies, mostly in industrialized countries where both AIDS incidence and the mortality resulting from AIDS have been declining. In this study, we make use of a cohort data of 138 AIDS patients in Taiwan, where the annual number of AIDS incidence is still increasing, to investigate the impact of HAART on survival time from onset of AIDS to death, by attempting to identify the association between patterns of CD4 counts and survival times for the HAART and non-HAART groups. Complications in data used, such as CD4 counts measured intermittently at different time points for differ...
In HAART and other follow-up clinical trials, both longitudinal and survival data are generated. Joi...
OBJECTIVE: To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starti...
OBJECTIVE: To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starti...
[[abstract]]We assessed the survival of 1,044 HIV-infected persons enrolled in three periods: period...
We assessed the survival of 1,044 HIV-infected persons enrolled in three periods: period 1, 1994 to ...
Objective. The aim of our study was to develop, on the basis of simple clinical data, predictive sho...
Received for publication February 6, 2002; accepted for publication March 10, 2003. To estimate the ...
(See the editorial commentary by Mocroft and Lundgren on pages 951–3) Objective. The aim of our stud...
OBJECTIVE: To estimate the effect of combined antiretroviral therapy (cART) on mortality among HIV-i...
OBJECTIVE: To estimate the effect of combined antiretroviral therapy (cART) on mortality among HIV-i...
Background: Most existing prognostic models for people living with HIV/AIDS (PLWHA) were derived fro...
We evaluated the changes in the progression to death and AIDS and in the mean level of CD4 lymphocyt...
To explain differences in survival in the first three years of combination anti-retroviral therapy (...
Objectives: To examine survival and progression to AIDS among HIV-infected patients after starting h...
OBJECTIVES: To examine survival and progression to AIDS among HIV-infected patients after starting h...
In HAART and other follow-up clinical trials, both longitudinal and survival data are generated. Joi...
OBJECTIVE: To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starti...
OBJECTIVE: To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starti...
[[abstract]]We assessed the survival of 1,044 HIV-infected persons enrolled in three periods: period...
We assessed the survival of 1,044 HIV-infected persons enrolled in three periods: period 1, 1994 to ...
Objective. The aim of our study was to develop, on the basis of simple clinical data, predictive sho...
Received for publication February 6, 2002; accepted for publication March 10, 2003. To estimate the ...
(See the editorial commentary by Mocroft and Lundgren on pages 951–3) Objective. The aim of our stud...
OBJECTIVE: To estimate the effect of combined antiretroviral therapy (cART) on mortality among HIV-i...
OBJECTIVE: To estimate the effect of combined antiretroviral therapy (cART) on mortality among HIV-i...
Background: Most existing prognostic models for people living with HIV/AIDS (PLWHA) were derived fro...
We evaluated the changes in the progression to death and AIDS and in the mean level of CD4 lymphocyt...
To explain differences in survival in the first three years of combination anti-retroviral therapy (...
Objectives: To examine survival and progression to AIDS among HIV-infected patients after starting h...
OBJECTIVES: To examine survival and progression to AIDS among HIV-infected patients after starting h...
In HAART and other follow-up clinical trials, both longitudinal and survival data are generated. Joi...
OBJECTIVE: To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starti...
OBJECTIVE: To estimate the prognosis over 5 years of HIV-1-infected, treatment-naive patients starti...